Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carl Zeiss Meditec AGSTU:AFX -2.14%78 Quick Ratio is 1.43 as of Sep. 2025, which is 47% below its 10-year median of 2.70. GuruFocus rates STU:AFX with a GF Score™ of 78/100 and a GF Value™ of €73.79 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 60.47% on this metric.
Carl Zeiss Meditec AG has a quick ratio of 1.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for Carl Zeiss Meditec AG's Quick Ratio or its related term are showing as below:
STU:AFX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.17 Med: 2.7 Max: 3.74
Current: 1.43
During the past 13 years, Carl Zeiss Meditec AG's highest Quick Ratio was 3.74. The lowest was 1.17. And the median was 2.70.
STU:AFX's Quick Ratio is ranked worse than 60.47% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 1.83
vs STU:AFX: 1.43
Carl Zeiss Meditec AG (STU:AFX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Carl Zeiss Meditec AG Quick Ratio Related Terms
Carl Zeiss Meditec AG Quick Ratio Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Carl Zeiss Meditec AG's Quick Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (STU:AFX) has a Quick Ratio of 1.43 as of Sep. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Carl Zeiss Meditec AG and its competitors. This is 47% below median its historical median of 2.70. Over the past decade, Carl Zeiss Meditec AG's Quick Ratio has ranged from 1.17 to 3.74. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #514 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 60.5%.
Is Carl Zeiss Meditec AG's Quick Ratio too high?
Carl Zeiss Meditec AG's current Quick Ratio of 1.43 is 47% below median its 10-year median of 2.70. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 3.74. The Medical Devices & Instruments industry median Quick Ratio is 1.83. Carl Zeiss Meditec AG's value of 1.43 is 21.9% below this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #514 out of 850 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Quick Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #514 out of 850 companies for Quick Ratio. This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median Quick Ratio is 1.83. Carl Zeiss Meditec AG's value of 1.43 is 21.9% below this benchmark. Historically, Carl Zeiss Meditec AG's own Quick Ratio has ranged from 1.17 to 3.74 over the past decade. While the company's 10-year median is 2.70 vs. the industry median of 1.83, Carl Zeiss Meditec AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.83, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current Quick Ratio of 1.43 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current Quick Ratio is 1.43, which is 47% below median its own 10-year median of 2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (STU:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is €73.79, compared to a current price of €30.24 — trading 59% below its estimated fair value. The current Quick Ratio is 1.43, which is 47% below median its 10-year median of 2.70 and 21.9% below the Medical Devices & Instruments industry median of 1.83. Carl Zeiss Meditec AG's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Carl Zeiss Meditec AG (STU:AFX), the current Quick Ratio is 1.43 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (STU:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of €30.24 is trading 59% below its estimated GF Value™ of €73.79.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for STU:AFX:
Quick Ratio: 1.43 (47% below median its 10-year median of 2.70)
GF Value™: €73.79 vs. price of €30.24 (59% below fair value)
Industry Position: 21.9% below the Medical Devices & Instruments median (#514 of 850)
No single metric tells the full story. See the STU:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
78GF Score
Get the complete analysis for STU:AFX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AFX has been successfully added to your 
